Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This multicentric pilot study was conducted in order to evaluate the feasibility of early interleukin-2 (IL2) after high dose chemotherapy requiring autologous bone marrow transplantation (ABMT). BCNU at 800 mg/m2 was followed, 3 days later, by the reinjection of the bone marrow cells. At day 4, IL2 at 18 x 10(6) i.u./m2/day was given as a continuous infusion during a minimum of 6 days (first phase of study) or for 6 more days after 1 day break (second phase of the study). Twenty patients were included. Toxicity was not negligible, with one toxic death, but IL2 therapy does not damage the haematological recovery of most patients. However, a 6-day IL2 treatment period only appears tolerable. In 18 evaluable patients, three responses were observed: one complete response (CR) of short duration in a non-Hodgkin's lymphoma, one CR (24 months +) and one partial response (PR) (6 months) in two patients with metastatic gastric adenocarcinoma. This study confirms that IL2, restricted to a 6-day treatment period, is feasible immediately after high-dose chemotherapy requiring ABMT without haematological problem in most patients. The response rate was unexpected for a pilot study and this combined therapy obviously requires further study.
 ...
PMID:Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study. 175 23

Developments in the therapeutic approach to Hodgkin's disease have resulted in excellent long-term survival statistics. However, these patients are at risk for second malignancies, most commonly acute myelogenous leukemia and non-Hodgkin's lymphoma. We present a patient who developed non-Hodgkin's lymphoma of the colon simulating adenocarcinoma 14 years after successful radiation therapy for Hodgkin's disease.
 ...
PMID:Development of non-Hodgkin's lymphoma of the colon after radiation therapy for Hodgkin's disease. 191 76

The association of gastric non-Hodgkin's lymphoma (NHL) and the subsequent development of gastric adenocarcinoma is an exceptional finding. In our series of 24 cases of primitive NHL of the stomach diagnosed between 1966 and 1985 only one developed gastric adenocarcinoma. It was a 38-year-old male with a gastric NHL of immunocytoma type and in the stage IE of the Ann Arbor classification. The patient was treated with subtotal gastrectomy and adjuvant radiotherapy. Twenty-seven months later an adenocarcinoma of the gastrojejunal anastomosis mucosa was found. In the review of the literature we have found 17 cases of this association. Gastric adenocarcinoma developed 3.5-34 years after the treatment of gastric NHL. The implicated factors in the development of this association are: gastric resection, chemotherapy, radiotherapy and NHL itself.
 ...
PMID:[Gastric adenocarcinoma following the treatment of a gastric non-Hodgkin's lymphoma]. 208 11

The exact risk of second cancer (S.C.) following treatment of testicular seminoma is not well determined in most series. At our institution, 122 patients with pure seminoma were treated by orchidectomy followed by radiation therapy from 1951 to 1986. Six were lost to follow-up. For the 116 remaining patients, the overall 5-, 10-, 15- and 20-year survival probability was 95%, 90%, 87%, and 84%, respectively. Eleven patients developed 12 second cancers, with a cumulative risk of 7%, 16%, and 16% at 10, 15, and 20 years, respectively. Overall, the risk of second cancer was increased (O/E = 1.97, p = 0.023). There were 3 controlateral seminoma (O/E = 50, p = 0.001), 2 transitional carcinoma of the bladder (O/E = 6.9, p = 0.035), 2 non-Hodgkin's lymphoma (N.S.), 1 acute myeloblastic leukemia, 1 chronic lymphocytic leukemia, 1 intracranial dysgerminoma, 1 rectal and 1 lung adenocarcinoma. Four tumors developed within the previously irradiated field (O/E = 2.2, N.S.). Excluding second seminoma, the overall risk of second cancer was not significant (O/E = 1.33). Five of the 11 patients with second cancer are currently alive without recurrent cancer. We conclude that patients treated for seminoma have an increased risk of second cancer but the overall prognosis remains excellent. The potential factors responsible for second cancer, including irradiation, are discussed.
 ...
PMID:The risk of second cancer (SC) in patients treated for testicular seminoma. 211 33

We reviewed the records of 107 patients with non-Hodgkin's lymphoma (NHL) to evaluate the relation between second primary neoplasms and the NHL immunophenotype. The incidence of second primary neoplasms was 3.7%. There were one case of hepatocellular carcinoma and 3 cases of gastric adenocarcinoma including one patient who had a history of metachronous malignant lymphomas. Three patients had B cell lymphoma with monoclonal IgM kappa phenotype, and one patient had follicular mixed cell type lymphoma with serum monoclonal IgM kappa. The dominant immunophenotype of B cell lymphomas in Japanese patients is IgM lambda. We believe that the association of the uncommon phenotype of IgM kappa with second primary neoplasms, especially gastric cancer, reflects an underlying genetic predisposition. NHL patients with IgM kappa phenotype should be evaluated carefully for second primary neoplasms.
 ...
PMID:Relationship between immunophenotype and the development of second primary neoplasms in patients with non-Hodgkin's lymphoma. 254 69

Squamous cell carcinoma and adenocarcinoma constitute the majority of malignancies of the esophagus. Although lymphoma may involve any part of the gastrointestinal tract either primarily or secondarily, esophageal involvement is rare. We describe two cases of primary esophageal non-Hodgkin's lymphoma and review the literature, with particular attention to roentgenographic studies, esophagoscopic findings, and endoscopic biopsy results.
 ...
PMID:Primary non-Hodgkin's lymphoma of the esophagus. 264 14

True annular malignancies of the small bowel with mucosal destruction and shelflike margins are generally thought to be caused by primary adenocarcinoma. At our institution, 18 annular malignancies were diagnosed radiographically in the small bowel by enteroclysis (16 cases) and conventional small bowel follow-through studies (2 cases) between 1977 and 1984. However, pathologic data revealed only 4 primary adenocarcinomas with 10 metastatic lesions (6 colon cancers, 2 malignant melanomas, 1 lung cancer, and 1 cervical cancer), 2 leiomyosarcomas, 1 non-Hodgkin's lymphoma, and 1 malignant carcinoid tumor. While these lesions may be indistinguishable radiographically, annular carcinomas tended to be short, relatively nonobstructing lesions; annular metastases (except those from malignant melanoma) tended to be highly obstructing lesions with significant narrowing and/or angulation of the bowel. Leiomyosarcomas, lymphoma, and metastases from malignant melanoma tended to be longer lesions with extensive ulceration, wider channels, and little or no evidence of obstruction. Nevertheless, surgical resection or biopsy of the lesion is ultimately required for a definitive diagnosis.
 ...
PMID:Annular malignancies of the small bowel. 379 59

A3/Kawakami was derived from ascitic lymphoma cells of a 68-year-old female patient with malignant lymphoma (non-Hodgkin's lymphoma, diffuse, large cell type) of the stomach and A4/Fukuda was derived from ascitic lymphoma cells of a 52-year-old female patient with double cancer of the colon (well-differentiated papillary adenocarcinoma and non-Hodgkin's lymphoma, diffuse, large cell type). The fresh ascitic lymphoma cells in the case of A3/Kawakami were surface immunoglobulin-positive, but the cultured A3/Kawakami cells no longer expressed any distinct markers. In the case of A4/Fukuda, the fresh ascitic lymphoma cells and cultured cells did not express any specific surface markers. Only 20% of A4/Fukuda cells were reactive with OKI1. However, a small amount of IgM could be detected in the cell extract and concentrated culture supernate of A4/Fukuda. In addition, A4/Fukuda cells heterotransplanted into anti-thymocyte sera-treated newborn hamster or athymic nude mice with a BALB/c genetic background were found to have weak surface immunoglobulin and distinct cytoplasmic immunoglobulin (gamma, mu). These data suggest that A4/Fukuda cells share the characteristics of the late differentiation stage of B-cell lineage (intermediate between mature B-cells and plasma cells). It was found that monoclonal antibodies, OKT4 and anti-Leu 3a, which are known to react specifically with inducer/helper T-cells, reacted to both A3/Kawakami and A4/Fukuda cells. The karyotypes of both A3/Kawakami and A4/Fukuda cells were very complicated but included some marker chromosomes such as 14q+.
 ...
PMID:Two novel cultured cell lines, A3/Kawakami and A4/Fukuda, derived from malignant lymphoma of B(non-T)-cell nature of the gastrointestinal tract. 660 97

The effects of metoprine administered orally every 2 weeks were studied in 71 evaluable adult patients with advanced malignant tumors. Two escalating dose schedules were explored in this phase I evaluation: (a) doses ranging from 20 to 65 mg/m2 without scheduled leucovorin, and (b) doses ranging from 100 to 300 mg/m2 with scheduled iv leucovorin. Thrombocytopenia was dose-limiting at 65 mg/m2 in the low-dose schedule; CNS toxicity was dose-limiting at 300 mg/m2 in the high-dose schedule. Occasionally leukopenia and mild nausea or vomiting were noted. Therapeutic responses were observed in patients with mycosis fungoides, non-Hodgkin's lymphoma, and adenocarcinoma of unknown origin. Phase II (disease-oriented) studies can appropriately be initiated with fortnightly metoprine at 50 mg/m2 without leucovorin. In the high-dose schedule, 225 mg/m2 of metoprine with 75 mg/m2 of iv leucovorin at 24 hours appears appropriate for good-risk patients; in marginal-risk patients, two doses of leucovorin should be given: 75 and 37.5 mg/m2 at 24 and 96 or 168 hours, respectively.
 ...
PMID:Phase I trial of metoprine in patients with advanced cancer. 696 32

Analysing 24 cases of gastric sarcomas of hemopoietic origin (22 non-Hodgkin's lymphomas, 2 Hodgkin's disease) and one instance of plasmacytoma, the authors review the general and radiologic characteristics of such uncommon affections. The gastric localizations of plasmocytic affections are rare, and of them, the ulcerated fungating manifestation of the lesser curvature is the most classical. In the course of Hodgkin's disease, the finding of gastric localization darkens the prognosis since it implies a Stage IV. Because of fibroblastic stroma-response, the images are radiologically similar to adenocarcinoma. On the other hand, the radiologic aspect of gastric localization of non-Hodgkin's lymphoma leads to preoperative diagnosis. -- radiologic images measuring at least 10 cm on their long axis in more than two-thirds of cases, -- clinical-radiologic discrepancy (discreet clinical findings and extensive radiologic evidence), -- infrequent stenotic varieties, -- relatively frequent combined forms (one-third of cases) and eventual simultaneous duodenal localization (about 10%).
 ...
PMID:[Malignant lymphoma of the stomach]. 738 Aug 69


1 2 3 4 5 6 7 8 9 Next >>